Positron emission tomography for prostate, bladder, and renal cancer

Seminars in Nuclear Medicine

Volumn 34, Issue 4, 2004, Pages 274-292

  Schöder, Heiko ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ANDROGEN RECEPTOR; ANDROSTANOLONE; CARBON 11; CHOLINE; FLUORINE 18; FUROSEMIDE; METHIONINE; PROSTATE SPECIFIC ANTIGEN;

ADRENAL CORTEX ADENOMA; BLADDER CANCER; BLADDER TUMOR; BONE METASTASIS; BONE SCINTISCANNING; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; DISEASE COURSE; HORMONAL THERAPY; HUMAN; IMAGING; KIDNEY CANCER; KIDNEY CARCINOMA; MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RADIOTHERAPY; RECURRENT DISEASE; RELAPSE; REVIEW; SENSITIVITY ANALYSIS; URINARY EXCRETION;

EID: 5544270813     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2004.06.004     Document Type: Article

References (180)

1. A. Jemal, R.C. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. N. Craft, C. Chhor, C. Tran Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process Cancer Res 59 1999 5030 5036
3. C.D. Chen, D.S. Welsbie, C. Tran Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39
4. H.I. Scher, G. Heller Clinical states in prostate cancer toward a dynamic model of disease progression Urology 55 2000 323 327
5. A.W. Partin, M.W. Kattan, E.N. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update JAMA 277 1997 1445 1451
6. M.L. Blute, E.J. Bergstralh, A.W. Partin Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer J Urol 164 2000 1591 1595
7. M. Graefen, P.I. Karakiewicz, I. Cagiannos A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men Urol Oncol 7 2002 141 146
8. D. Gleason Histological grading and clinical staging of prostatic carcinoma The Prostate T. Tannenbaum Urologic Pathology 1977 Lea & Febiger Philadelphia, PA 171 197
9. M.W. Kattan, T.M. Wheeler, P.T. Scardino Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer J Clin Oncol 17 1999 1499 1507
10. A.V. D'Amico, R. Whittington, M. Schnall The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer Cancer 75 1995 2368 2372
11. M.W. Kattan, J.A. Eastham, A.M. Stapleton A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766 771
12. M.D. Rifkin, E.A. Zerhouni, C.A. Gatsonis Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial N Engl J Med 323 1990 621 626
13. J.A. Smith Jr, P.T. Scardino, M.I. Resnick Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate results of a prospective, multi-institutional trial J Urol 157 1997 902 906
14. H. Hricak, G.C. Dooms, R.B. Jeffrey Prostatic carcinoma staging by clinical assessment, CT, and MR imaging Radiology 162 1987 331 336
15. K.K. Yu, H. Hricak Imaging prostate cancer Radiol Clin North Am 38 2000 59 85
16. K.K. Yu, H. Hricak, R. Alagappan Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging multivariate feature analysis Radiology 202 1997 697 702
17. C. Bartolozzi, I. Menchi, R. Lencioni Local staging of prostate carcinoma with endorectal coil MRI correlation with whole-mount radical prostatectomy specimens Eur Radiol 6 1996 339 345
18. C.M. Tempany, X. Zhou, E.A. Zerhouni Staging of prostate cancer results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques Radiology 192 1994 47 54
19. J. Kurhanewicz, D.B. Vigneron, S.J. Nelson Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer Neoplasia 2 2000 166 189
20. K.K. Yu, J. Scheidler, H. Hricak Prostate cancer prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging Radiology 213 1999 481 488
21. O. Warburg Metabolism of Tumors 1931 Richard R. Smith New York, NY
22. G. Singh, C.L. Lakkis, R. Laucirica Regulation of prostate cancer cell division by glucose J Cell Physiol 180 1999 431 438
23. F. Rossi, M. Grzeskowiak, V. Della Bianca De novo synthesis of diacylglycerol from glucose A new pathway of signal transduction in human neutrophils stimulated during phagocytosis of beta-glucan particles. J Biol Chem 266 1991 8034 8038
24. D.B. Agus, D.W. Golde, G. Sgouros Positron emission tomography of a human prostate cancer xenograft association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal Cancer Res 58 1998 3009 3014
25. M.A. Seltzer, Z. Barbaric, A. Belldegrun Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer J Urol 162 1999 1322 1328
26. N. Oyama, H. Akino, H. Kanamaru 11C-acetate PET imaging of prostate cancer J Nucl Med 43 2002 181 186
27. K. Herrmann, H. Schöder, S. Eberhard FDG PET for the detection of recurrent/metastatic prostate carcinoma in patients with rising PSA after radical prostatectomy J Nucl Med 45 2004 359 (abstr)
28. C. Hofer, C. Laubenbacher, T. Block Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy Eur Urol 36 1999 31 35
29. P.J. Effert, R. Bares, S. Handt Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose J Urol 155 1996 994 998
30. P.D. Shreve, H.B. Grossman, M.D. Gross Metastatic prostate cancer initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose Radiology 199 1996 751 756
31. E. Fricke, S. Machtens, M. Hofmann Positron emission tomography with (11)C-acetate and (18)F-FDG in prostate cancer patients Eur J Nucl Med Mol Imaging 30 2003 607 611
32. S.M. Larson, M. Morris, I. Gunther Tumor localization of 16beta-(18)F-fluoro-5alpha-dihydrotestosterone versus (18)F-FDG in patients with progressive, metastatic prostate cancer J Nucl Med 45 2004 366 373
33. M.J. Morris, T. Akhurst, I. Osman Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer Urology 59 2002 913 918
34. R. Nunez, H.A. Macapinlac, H.W. Yeung Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer J Nucl Med 43 2002 46 55
35. A. Turlakow, S.M. Larson, F. Coakley Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose comparison of filtered back projection and iterative reconstruction with segmented attenuation correction Q J Nucl Med 45 2001 235 244
36. P.D. Shreve, M.D. Gross Imaging of the pancreas and related diseases with PET carbon-11-acetate J Nucl Med 38 1997 1305 1310
37. P. Shreve, P.C. Chiao, H.D. Humes Carbon-11-acetate PET imaging in renal disease J Nucl Med 36 1995 1595 1601
38. N. Oyama, T.R. Miller, F. Dehdashti 11C-Acetate PET Imaging of Prostate Cancer Detection of Recurrent Disease at PSA Relapse J Nucl Med 44 2003 549 555
39. J. Kotzerke, B.G. Volkmer, B. Neumaier Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer Eur J Nucl Med Mol Imaging 29 2002 1380 1384
40. D. Ponde, N. Oyama, C. Dence 18F fluoroacetate, an analogue on 11C acetate for tumor imaging J Nucl Med 44 2003 296 (abstr)
41. A. Matthies, S. Ezziddin, E.M. Ulrich Imaging of prostate cancer metastases with (18)F-fluoroacetate using PET/CT Eur J Nucl Med Mol Imaging 31 2004 797
42. M. Yoshimoto, A. Waki, Y. Yonekura Characterization of acetate metabolism in tumor cells in relation to cell proliferation acetate metabolism in tumor cells Nucl Med Biol 28 2001 117 122
43. J.V. Swinnen, P.P. Van Veldhoven, L. Timmermans Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains Biochem Biophys Res Commun 302 2003 898 903
44. J.J. Armbrecht, D.B. Buxton, H.R. Schelbert Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium Circulation 81 1990 1594 1605
45. J.J. Armbrecht, D.B. Buxton, R.C. Brunken Regional myocardial oxygen consumption determined noninvasively in humans with [1-11C]acetate and dynamic positron tomography Circulation 80 1989 863 872
46. D.B. Buxton, C.A. Nienaber, A. Luxen Noninvasive quantitation of regional myocardial oxygen consumption in vivo with [1-11C]acetate and dynamic positron emission tomography Circulation 79 1989 134 142
47. L.C. Costello, R.B. Franklin The intermediary metabolism of the prostate a key to understanding the pathogenesis and progression of prostate malignancy Oncology 59 2000 269 282
48. L.C. Costello, Y. Liu, R.B. Franklin Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells J Biol Chem 272 1997 28875 28881
49. J.V. Swinnen, G. Verhoeven Androgens and the control of lipid metabolism in human prostate cancer cells J Steroid Biochem Mol Biol 65 1998 191 198
50. J.V. Swinnen, T. Roskams, S. Joniau Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer Int J Cancer 98 2002 19 22
51. K. Simons, D. Toomre Lipid rafts and signal transduction Nat Rev Mol Cell Biol 1 2000 31 39
52. A.K. Rouquette-Jazdanian, C. Pelassy, J.P. Breittmayer Metabolic labeling of membrane microdomains/rafts in Jurkat cells indicates the presence of glycerophospholipids implicated in signal transduction by the CD3 T-cell receptor Biochem J 363 2002 645 655
53. T. Kato, E. Tsukamoto, Y. Kuge Accumulation of [(11)C]acetate in normal prostate and benign prostatic hyperplasia comparison with prostate cancer Eur J Nucl Med Mol Imaging 29 2002 1492 1495
54. S.H. Zeisel, J.K. Blusztajn Choline and human nutrition Annu Rev Nutr 14 1994 269 296
55. S. Ratnam, C. Kent Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines Arch Biochem Biophys 323 1995 313 322
56. E. Ackerstaff, B.R. Pflug, J.B. Nelson Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells Cancer Res 61 2001 3599 3603
57. R. Katz-Brull, H. Degani Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method Anticancer Res 16 1996 1375 1380
58. T. Hara, N. Kosaka, N. Shinoura PET imaging of brain tumor with [methyl-11C]choline J Nucl Med 38 1997 842 847
59. T. Hara, N. Kosaka, H. Kishi PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 1998 990 995
60. T. Hara, K. Inagaki, N. Kosaka Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET J Nucl Med 41 2000 1507 1513
61. O. Kobori, Y. Kirihara, N. Kosaka Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose a novel method of preoperative lymph node staging Cancer 86 1999 1638 1648
62. D.T. Price, R.E. Coleman, R.P. Liao Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer J Urol 168 2002 273 280
63. M. Picchio, C. Messa, C. Landoni Value of [11C]choline-positron emission tomography for re-staging prostate cancer a comparison with [18F] fluorodeoxyglucose-positron emission tomography J Urol 169 2003 1337 1340
64. J. Kotzerke, J. Prang, B. Neumaier Experience with carbon-11 choline positron emission tomography in prostate carcinoma Eur J Nucl Med 27 2000 1415 1419
65. I.J. de Jong, J. Pruim, P.H. Elsinga Visualization of prostate cancer with 11C-choline positron emission tomography Eur Urol 42 2002 18 23
66. I.J. de Jong, J. Pruim, P.H. Elsinga Preoperative staging of pelvic lymph nodes in prostate cancer by (11)C-choline PET J Nucl Med 44 2003 331 335
67. I.J. de Jong, J. Pruim, P.H. Elsinga 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer Eur Urol 44 2003 32 38 discussion 38-39
68. A. Roivainen, S. Forsback, T. Gronroos Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography Eur J Nucl Med 27 2000 25 32
69. T. Hara, N. Kosaka, H. Kishi Development of (18)F-fluoroethylcholine for cancer imaging with PET synthesis, biochemistry, and prostate cancer imaging J Nucl Med 43 2002 187 199
70. T.R. DeGrado, R.E. Coleman, S. Wang Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography initial findings in prostate cancer Cancer Res 61 2001 110 117
71. T.R. DeGrado, S.W. Baldwin, S. Wang Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers J Nucl Med 42 2001 1805 1814
72. T.R. DeGrado, R.E. Reiman, D.T. Price Pharmacokinetics and radiation dosimetry of 18F-fluorocholine J Nucl Med 43 2002 92 96
73. E. Sutinen, M. Nurmi, A. Roivainen Kinetics of [(11)C]choline uptake in prostate cancer a PET study [correction for stydy] Eur J Nucl Med Mol Imaging 31 2004 317 324
74. M.T. Wyss, B. Weber, M. Honer 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET Eur J Nucl Med Mol Imaging 31 2004 312 316
75. H. Miyazawa, T. Arai, M. Iio PET imaging of non-small-cell lung carcinoma with carbon-11-methionine relationship between radioactivity uptake and flow-cytometric parameters J Nucl Med 34 1993 1886 1891
76. P. Lindholm, S. Leskinen, M. Lapela Carbon-11-methionine uptake in squamous cell head and neck cancer J Nucl Med 39 1998 1393 1397
77. P. Lindholm, S. Leskinen, K. Nagren Carbon-11-methionine PET imaging of malignant melanoma J Nucl Med 36 1995 1806 1810
78. T. Ogawa, F. Shishido, I. Kanno Cerebral glioma Evaluation with methionine PET Radiology 186 1993 45 53
79. O. Schober, C. Duben, G. Meyer Nonselective transport of [11C-methyl]-L- and D-methionine into a malignant glioma Eur J Nucl Med 13 1987 103 105
80. J. Hatazawa, K. Ishiwata, M. Itoh Quantitative evaluation of L-[methyl]-11C methionine uptake in tumor using positron emission tomography J Nucl Med 30 1989 1809 1813
81. R. Kubota, K. Kubota, S. Yamada Methionine uptake by tumor tissue A microautoradiographic comparison with FDG J Nucl Med 36 1995 484 492
82. S. Nilsson, K. Kalkner, C. Ginman C-11 methionine positron emission tomography in the management of prostatic carcinoma Antibody Immunconj Radiopharm 8 1995 23
83. H.A. Macapinlac, J.L. Humm, T. Akhurst Differential metabolism and pharmacokinetics of L-[1-(11)C]-methionine and 2-[(18)F] fluoro-2-deoxy-D- glucose (FDG) in androgen independent prostate cancer Clin Positron Imaging 2 1999 173 181
84. N. Craft, C.L. Sawyers Mechanistic concepts in androgen-dependence of prostate cancer Cancer Metastasis Rev 17 1998 421 427
85. T.A. Bonasera, J.P. O'Neil, M. Xu Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons J Nucl Med 37 1996 1009 1015
86. J.D. Chandler, E.D. Williams, J.L. Slavin Expression and localization of GLUT1 and GLUT12 in prostate carcinoma Cancer 97 2003 2035 2042
87. I.J. Liu, M.B. Zafar, Y.H. Lai Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer Urology 57 2001 108 111
88. J.A. Smith Jr, J.P. Seaman, J.B. Gleidman Pelvic lymph node metastasis from prostatic cancer influence of tumor grade and stage in 452 consecutive patients J Urol 130 1983 290 292
89. W.S. Bundrick, D.J. Culkin, J.A. Mata Evaluation of the current incidence of nodal metastasis from prostate cancer J Surg Oncol 52 1993 269 271
90. J.F. Danella, J.B. deKernion, R.B. Smith The contemporary incidence of lymph node metastases in prostate cancer implications for laparoscopic lymph node dissection J Urol 149 1993 1488 1491
91. J. Eastham, P. Scardino Radical Prostatectomy, in Campbell's Urology 1998 Saunders Philadelphia, PA 2547 2561
92. M. Ohori, T.M. Wheeler, J.K. Dunn The pathological features and prognosis of prostate cancer detectable with current diagnostic tests J Urol 152 1994 1714 1720
93. P. Bader, F.C. Burkhard, R. Markwalder Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168 2002 514 518 discussion 518
94. A. Heidenreich, Z. Varga, R. Von Knobloch Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy high incidence of lymph node metastasis J Urol 167 2002 1681 1686
95. R.A. Edelstein, A.L. Zietman, A. de las Morenas Implications of prostate micrometastases in pelvic lymph nodes An archival tissue study Urology 47 1996 370 375
96. L. Cheng, H. Zincke, M.L. Blute Risk of prostate carcinoma death in patients with lymph node metastasis Cancer 91 2001 66 73
97. H. Zincke, W. Lau, E. Bergstralh Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer J Urol 166 2001 2208 2215
98. M. Graefen, P.I. Karakiewicz, I. Cagiannos Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer J Clin Oncol 20 2002 951 956
99. L. Cheng, E.J. Bergstralh, J.C. Cheville Cancer volume of lymph node metastasis predicts progression in prostate cancer Am J Surg Pathol 22 1998 1491 1500
100. G.D. Steinberg, J.I. Epstein, S. Piantadosi Management of stage D1 adenocarcinoma of the prostate the Johns Hopkins experience 1974 to 1987 J Urol 144 1990 1425 1432
101. T.M. Seay, M.L. Blute, H. Zincke Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation J Urol 159 1998 357 364
102. R. Oyen, F. van Poppel, W. van de Voorde Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy Prospective study of 285 patients Radiology 190 1994 315 322
103. J.S. Wolf Jr, M. Cher, M. Dall'era The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy J Urol 153 1995 993 999
104. R. Tiguert, E.L. Gheiler, M.V. Tefilli Lymph node size does not correlate with the presence of prostate cancer metastasis Urology 53 1999 367 371
105. R.C. Flanigan, T.C. McKay, M. Olson Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy Urology 48 1996 428 432
106. M.G. Harisinghani, J. Barentsz, P.F. Hahn Noninvasive detection of clinically occult lymph-node metastases in prostate cancer N Engl J Med 348 2003 2491 2499
107. H. Takashima, M. Egawa, T. Imao Validity of sentinel lymph node concept for patients with prostate cancer J Urol 171 2004 2268 2271
108. F. Wawroschek, H. Vogt, H. Wengenmair Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases Urol Int 70 2003 303 310
109. F.M. Chybowski, J.J. Keller, E.J. Bergstralh Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer prostate specific antigen is superior to all other clinical parameters J Urol 145 1991 313 318
110. C.T. Lee, J.E. Oesterling Using prostate-specific antigen to eliminate the staging radionuclide bone scan Urol Clin North Am 24 1997 389 394
111. R. Heicappell, V. Muller-Mattheis, M. Reinhardt Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose Eur Urol 36 1999 582 587
112. S.D. Yeh, M. Imbriaco, S.M. Larson Detection of bony metastases of androgen-independent prostate cancer by PET-FDG Nucl Med Biol 23 1996 693 697
113. E. Even-Sapir, U. Metser, G. Flusser Assessment of malignant skeletal disease initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT J Nucl Med 45 2004 272 278
114. A.K. Leventis, S.F. Shariat, K.M. Slawin Local recurrence after radical prostatectomy correlation of US features with prostatic fossa biopsy findings Radiology 219 2001 432 439
115. J.E. Fowler Jr, J. Brooks, P. Pandey Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy J Urol 153 1995 1011 1014
116. J.A. Connolly, K. Shinohara, J.C. Presti Jr Local recurrence after radical prostatectomy characteristics in size, location, and relationship to prostate-specific antigen and surgical margins Urology 47 1996 225 231
117. P.C. Albertsen, J.A. Hanley, L.C. Harlan The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer a population based analysis J Urol 163 2000 1138 1143
118. P. Johnstone, T. GJ, R.H. Riffenburgh Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients Urol Oncol 3 1997 108 112
119. S. Kramer, J. Gorich, H.W. Gottfried Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy Br J Radiol 70 1997 995 999
120. J.D. Cox, M.J. Gallagher, E.H. Hammond American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statements on radiation therapy of prostate cancer guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy J Clin Oncol 17 1999 1155
121. J.W. Turner, D.R. Hawes, R.D. Williams Magnetic resonance imaging for detection of prostate cancer metastatic to bone J Urol 149 1993 1482 1484
122. G.M. Freedman, W.G. Negendank, G.R. Hudes Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer Urology 54 1999 118 123
123. T. Sella, L.H. Schwartz, P.W. Swindle Suspected local recurrence after radical prostatectomy endorectal coil MR imaging Radiology 231 2004 379 385
124. J.M. Silverman, T.L. Krebs MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy Am J Roentgenol 168 1997 379 385
125. D.K. Ornstein, J.W. Colberg, K.S. Virgo Evaluation and management of men whose radical prostatectomies failed results of an international survey Urology 52 1998 1047 1054
126. M.L. Cher, F.J. Bianco Jr, J.S. Lam Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy J Urol 160 1998 1387 1391
127. C.J. Kane, C.L. Amling, P.A. Johnstone Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy Urology 61 2003 607 611
128. P. Sabbatini, S.M. Larson, A. Kremer Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer J Clin Oncol 17 1999 948 957
129. M. Noguchi, H. Kikuchi, M. Ishibashi Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer Br J Cancer 88 2003 195 201
130. J. Rigaud, R. Tiguert, L. Le Normand Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy J Urol 168 2002 1423 1426
131. G. Antoch, F.M. Vogt, L.S. Freudenberg Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology JAMA 290 2003 3199 3206
132. Panel ASfTRaOC Consensus Statements on Radiation Therapy of Prostate Cancer Guidelines for Prostate Re-Biopsy After Radiation and for Radiation Therapy With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy J Clin Oncol 17 1999 1155 1163
133. D.P. Petrylak Chemotherapy for advanced hormone refractory prostate cancer Urology 54 1999 30 35
134. M.A. Khan, M.A. Carducci, A.W. Partin The evolving role of docetaxel in the management of androgen independent prostate cancer J Urol 170 2003 1709 1716
135. M.A. Eisenberger, B.A. Blumenstein, E.D. Crawford Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N Engl J Med 339 1998 1036 1042
136. B. Seckin, C.T. Anthony, B. Murphy Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer? World J Urol 14 suppl 1 1996 S26 S29
137. J.A. Schneider, C.R. Divgi, A.M. Scott Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer J Nucl Med 35 1994 1748 1752
138. B.J. McNeil Value of bone scanning in neoplastic disease Semin Nucl Med 14 1984 277 286
139. N. Oyama, H. Akino, Y. Suzuki FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation Nucl Med Commun 22 2001 963 969
140. N. Oyama, J. Kim, L.A. Jones MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model Nucl Med Biol 29 2002 783 790
141. N. Oyama, D.E. Ponde, C. Dence Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation J Nucl Med 45 2004 519 525
142. N. Shimizu, H. Masuda, H. Yamanaka Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy J Urol 161 1999 608 609
143. R.J. Wong, D.T. Lin, H. Schoder Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma J Clin Oncol 20 2002 4199 4208
144. J.F. Vansteenkiste, S.G. Stroobants, P.J. Dupont Leuven Lung Cancer Group Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy- glucose-positron emission tomography scan in non-small-cell lung cancer An analysis of 125 cases J Clin Oncol 17 1999 3201 3206
145. J.F. Eary, F. O'Sullivan, Y. Powitan Sarcoma tumor FDG uptake measured by PET and patient outcome a retrospective analysis Eur J Nucl Med Mol Imaging 29 2002 1149 1154
146. N. Oyama, H. Akino, Y. Suzuki Prognostic value of 2-deoxy-2-[F-18]fluoro- D-glucose positron emission tomography imaging for patients with prostate cancer Mol Imaging Biol 4 2002 99 104
147. R.J. Motzer, N.H. Bander, D.M. Nanus Renal-cell carcinoma N Engl J Med 335 1996 865 875
148. S. Hilton Imaging of renal cell carcinoma Semin Oncol 27 2000 150 159
149. H.H. Schreyer, M.M. Uggowitzer, A. Ruppert-Kohlmayr Helical CT of the urinary organs Eur Radiol 12 2002 575 591
150. L. Kopka, U. Fischer, G. Zoeller Dual-phase helical CT of the kidney Value of the corticomedullary and nephrographic phase for evaluation of renal lesions and preoperative staging of renal cell carcinoma AJR Am J Roentgenol 169 1997 1573 1578
151. R.J. Zagoria, R.E. Bechtold, R.B. Dyer Staging of renal adenocarcinoma role of various imaging procedures Am J Roentgenol 164 1995 363 370
152. S. Margaritora, V. Porziella, A. D'Andrilli Pulmonary metastases can accurate radiological evaluation avoid thoracotomic approach? Eur J Cardiothorac Surg 21 2002 1111 1114
153. S. Diederich, M. Semik, M.G. Lentschig Helical CT of pulmonary nodules in patients with extrathoracic malignancy CT-surgical correlation Am J Roentgenol 172 1999 353 360
154. R.L. Wahl, J. Harney, G. Hutchins Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose pilot animal and human studies J Urol 146 1991 1470 1474
155. R. Bachor, J. Kotzerke, S.N. Reske [Lymph node staging of bladder neck carcinoma with positron emission tomography] Urologe A 38 1999 46 50
156. S. Ramdave, G.W. Thomas, S.U. Berlangieri Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma J Urol 166 2001 825 830
157. D.E. Kang, R.L. White Jr, J.H. Zuger Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma J Urol 171 2004 1806 1809
158. H. Miyakita, M. Tokunaga, H. Onda Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer Int J Urol 9 2002 15 18
159. B.C. Leibovich, M.L. Blute, J.C. Cheville Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma a stratification tool for prospective clinical trials Cancer 97 2003 1663 1671
160. V. Ficarra, R. Righetti, S. Pilloni Prognostic factors in patients with renal cell carcinoma retrospective analysis of 675 cases Eur Urol 41 2002 190 198
161. J.P. Kavolius, D.P. Mastorakos, C. Pavlovich Resection of metastatic renal cell carcinoma J Clin Oncol 16 1998 2261 2266
162. G.V. Raj, A.W. Partin, T.J. Polascik Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy Cancer 94 2002 987 996
163. H. Jadvar, H.M. Kherbache, J.K. Pinski Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma Clin Nephrol 60 2003 395 400
164. A. Safaei, R. Figlin, C.K. Hoh The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer Clin Nephrol 57 2002 56 62
165. N.S. Majhail, J.L. Urbain, J.M. Albani F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma J Clin Oncol 21 2003 3995 4000
166. G. Dalbagni, E. Genega, M. Hashibe Cystectomy for bladder cancer a contemporary series J Urol 165 2001 1111 1116
167. M.A. Ghoneim, M.M. el-Mekresh, M.A. el-Baz Radical cystectomy for carcinoma of the bladder Critical evaluation of the results in 1,026 cases J Urol 158 1997 393 399
168. J.P. Stein, G. Lieskovsky, R. Cote Radical cystectomy in the treatment of invasive bladder cancer long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
169. I. Frank, J.C. Cheville, M.L. Blute Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy Clinicopathologic features associated with outcome Cancer 97 2003 2425 2431
170. M.L. Paik, M.J. Scolieri, S.L. Brown Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy J Urol 163 2000 1693 1696
171. O. Yaman, S. Baltaci, N. Arikan Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour Comparison with final pathological stage in invasive bladder carcinoma Br J Urol 78 1996 197 200
172. G.J. Jager, J.O. Barentsz, G.O. Oosterhof Pelvic adenopathy in prostatic and urinary bladder carcinoma MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence AJR Am J Roentgenol 167 1996 1503 1507
173. B. Kim, R.C. Semelka, S.M. Ascher Bladder tumor staging comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging Radiology 193 1994 239 245
174. I.J. de Jong, J. Pruim, P.H. Elsinga Visualisation of bladder cancer using (11)C-choline PET first clinical experience Eur J Nucl Med Mol Imaging 29 2002 1283 1288
175. S. Kosuda, P.V. Kison, R. Greenough Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer Eur J Nucl Med 24 1997 615 620
176. H. Schoder, Y.E. Erdi, S.M. Larson PET/CT A new imaging technology in nuclear medicine Eur J Nucl Med Mol Imaging 30 2003 1419 1437
177. R. Bar-Shalom, N. Yefremov, L. Guralnik Clinical performance of PET/CT in evaluation of cancer additional value for diagnostic imaging and patient management J Nucl Med 44 2003 1200 1209
178. H. Ahlstrom, P.U. Malmstrom, H. Letocha Positron emission tomography in the diagnosis and staging of urinary bladder cancer Acta Radiol 37 1996 180 185
179. H.M. Deloar, T. Fujiwara, T. Nakamura Estimation of internal absorbed dose of L-[methyl-11C]methionine using whole-body positron emission tomography Eur J Nucl Med 25 1998 629 633
180. M.A. Seltzer, S.A. Jahan, R. Sparks Radiation dose estimates in humans for (11)C-acetate whole-body PET J Nucl Med 45 2004 1233 1236